Phibro Animal Health Corporation (PAHC) Spending and interest coverage
- R&D / revenue · 12 months: Value 1.62%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.11%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 1.62% | Research and development expense / revenue. Period ending 2026-06-30. $24.55M ÷ $1.52B × 100 ≈ 1.62% |
| Stock-based compensation / revenue · 12 months | 0.11% | Share-based compensation / revenue. Period ending 2026-06-30. $1.60M ÷ $1.52B × 100 ≈ 0.11% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 24.55M USD | Research and Development Expense |
| Revenue | 1.52B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 1.60M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 194.40M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $24.55M | $1.52B | $1.60M | $194.40M | (m) | 1.62% | 0.11% | (m) | (m) |
| 2026-03-31 | (m) | $1.50B | $1.36M | $179.96M | (m) | (m) | 0.09% | (m) | (m) |
| 2025-12-31 | (m) | $1.46B | $1.13M | $168.82M | (m) | (m) | 0.08% | (m) | (m) |
| 2025-09-30 | (m) | $1.40B | $877.00K | $144.03M | (m) | (m) | 0.06% | (m) | (m) |
| 2025-06-30 | $23.73M | $1.30B | $717.00K | $110.47M | (m) | 1.83% | 0.06% | (m) | (m) |
| 2025-03-31 | (m) | $1.19B | $717.00K | $95.16M | (m) | (m) | 0.06% | (m) | (m) |
| 2024-12-31 | (m) | $1.11B | $673.00K | $81.57M | (m) | (m) | 0.06% | (m) | (m) |
| 2024-09-30 | (m) | $1.05B | $573.00K | $71.74M | (m) | (m) | 0.05% | (m) | (m) |
| 2024-06-30 | $29.19M | $1.02B | $475.00K | $53.31M | (m) | 2.87% | 0.05% | (m) | (m) |
| 2024-03-31 | (m) | $999.56M | (m) | $58.66M | $22.46M | (m) | (m) | 2.61× | Reported |
| 2023-12-31 | (m) | $982.01M | (m) | $57.29M | $21.72M | (m) | (m) | 2.64× | Reported |
| 2023-09-30 | (m) | $976.72M | (m) | $57.44M | $20.63M | (m) | (m) | 2.78× | Reported |
| 2023-06-30 | $24.39M | $977.89M | (m) | $71.85M | $18.68M | 2.49% | (m) | 3.85× | Reported |
| 2023-03-31 | (m) | $978.11M | (m) | $70.97M | $16.64M | (m) | (m) | 4.26× | Reported |
| 2022-12-31 | (m) | $972.05M | (m) | $71.61M | $14.85M | (m) | (m) | 4.82× | Reported |
| 2022-09-30 | (m) | $960.12M | (m) | $78.06M | $13.32M | (m) | (m) | 5.86× | Reported |
| 2022-06-30 | $20.83M | $942.26M | (m) | $78.99M | $12.69M | 2.21% | (m) | 6.22× | Reported |
| 2022-03-31 | (m) | $907.27M | $0.00 | $75.26M | $13.33M | (m) | 0.00% | 5.65× | Reported |
| 2021-12-31 | (m) | $879.38M | $0.00 | $76.20M | $13.30M | (m) | 0.00% | 5.73× | Reported |
| 2021-09-30 | (m) | $852.82M | $564.00K | $73.79M | $13.67M | (m) | 0.07% | 5.40× | Reported |
| 2021-06-30 | $17.76M | $833.35M | $1.13M | $74.87M | $13.72M | 2.13% | 0.14% | 5.46× | Reported |
| 2021-03-31 | (m) | $798.96M | $1.69M | $73.83M | $12.85M | (m) | 0.21% | 5.75× | Reported |
| 2020-12-31 | (m) | $797.97M | $2.26M | $75.02M | $13.43M | (m) | 0.28% | 5.59× | Reported |
| 2020-09-30 | (m) | $805.83M | $2.26M | $74.73M | $13.89M | (m) | 0.28% | 5.38× | Reported |
| 2020-06-30 | $13.74M | $800.35M | $2.26M | $69.19M | $14.61M | 1.72% | 0.28% | 4.74× | Reported |
| 2020-03-31 | (m) | (m) | $2.26M | $63.17M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $2.26M | $64.42M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | (m) | $2.26M | $70.52M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $12.08M | (m) | $2.26M | $83.23M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $835.90M | (m) | $97.24M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $839.07M | (m) | $101.16M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $826.72M | (m) | $99.39M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $10.00M | $819.98M | (m) | $98.93M | (m) | 1.22% | (m) | (m) | (m) |
| 2018-03-31 | (m) | $803.03M | (m) | $96.34M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $783.98M | (m) | $99.82M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $769.71M | (m) | $98.51M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $9.44M | $764.28M | (m) | $97.93M | (m) | 1.24% | (m) | (m) | (m) |
| 2017-03-31 | (m) | $758.62M | (m) | $94.51M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $752.22M | (m) | $85.71M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | (m) | $752.39M | (m) | $85.70M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $11.03M | $751.53M | (m) | $85.74M | (m) | 1.47% | (m) | (m) | (m) |
| 2016-03-31 | (m) | $747.30M | (m) | $86.61M | $16.01M | (m) | (m) | 5.41× | Reported |
| 2015-12-31 | (m) | $751.34M | (m) | $87.25M | $15.34M | (m) | (m) | 5.69× | Reported |
| 2015-09-30 | (m) | $748.25M | (m) | $84.42M | $14.87M | (m) | (m) | 5.68× | Reported |
| 2015-06-30 | $9.51M | $748.59M | (m) | $87.67M | $14.55M | 1.27% | (m) | 6.02× | Reported |
| 2015-03-31 | (m) | $747.32M | (m) | $79.76M | $17.29M | (m) | (m) | 4.61× | Reported |
| 2014-12-31 | (m) | $733.09M | (m) | $75.27M | $21.43M | (m) | (m) | 3.51× | Reported |
| 2014-09-30 | (m) | $717.14M | (m) | $72.50M | $25.67M | (m) | (m) | 2.82× | Reported |
| 2014-06-30 | $8.21M | $691.91M | (m) | $63.79M | $29.89M | 1.19% | (m) | 2.13× | Reported |
| 2014-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $661.86M | (m) | $62.78M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $653.27M | (m) | $59.92M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $6.64M | $653.15M | (m) | $56.73M | $31.38M | 1.02% | (m) | 1.81× | Reported |
| 2013-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $7.19M | $654.10M | (m) | $49.33M | $31.44M | 1.10% | (m) | 1.57× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.